Atty's Docket No.: P29138 Application No.: 10/564,407

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

applicants: Akiko ITAI et al. Group Art Unit: 4173

: 10/564,407 Examiner : Paul W. DICKINSON

(National Stage of PCT/JP2004/010558)

A lied: July 16, 2004 Confirmation No.: 3483

For : MEDICAMENT FOR TREATMENT OF DERMAL PIGMENTATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop <u>AMENDMENT</u>
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statement filed July 3, 2008, Applicants hereby bring to the attention of the Examiner the following documents:

- (1) U.S. Patent No. 3,332,996 (ZERWECK et al.), July 25, 1967;
- (2) MACIELAG et al. "Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria", Journal of Medicinal Chemistry, vol. 41, 1998, pp. 2939-2945;
- (3) HLASTA et al. "Novel Inhibitors of Bacterial Two-Component Systems with Gram
 Positive Antibacterial Activity: Pharmacophore Identification Based on the Screening
 Hit Closantel", Bioorganic and Medicinal Chemistry Letters, vol. 8, 1998, pp. 19231928.

Atty's Docket No.: P29138 Application No.: 10/564,407

signed and initialed copy of the PTO-1449 Form with the next official communication.

Copies of the above-listed documents (with the exception if the U.S. Patent) are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a

Further to 37 C.F.R. §1.98 (a)(2)(ii), a copy of the U.S. patent cited above is not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

· If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

Akiko ITAI et al

Bruce H. Bernstein

Reg. No. 29,027

February 5, 2008 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

Stephen M. Roylance Reg. No. 31,296